ABT.US Weekly Report · 2026-W37
Week Overview
Abbott declined 5.89% this week, falling from 108.33 to 101.95, hitting a two-month low. The intra-week range compressed to just 2.61%, indicating convergence rather than volatile swings. Capital flows show a structural divergence: institutional buyers maintained steady inflows while retail investors exited, creating a noteworthy mismatch. Valuations remain at historical lows, yet deteriorating quarterly profitability metrics are weighing on the stock price.
Price Action
ABT fell from 108.33 to 101.95 this week, representing a weekly decline of -5.89%. The high was 104.18 and the low was 101.49, with intra-week volatility (high minus low divided by opening price) of just 2.61%, indicating price consolidation within a tight band with no clear directional breakout.
Weekly volume totaled 8,398,311 shares worth $857.9 million. Examining the 60-day K-line history, except for the significant volume spike mid-July, trading volume has gradually declined since late August. This week’s volume sits at a moderate level relative to recent weeks. Turnover rate of 0.49% is consistent with recent averages.
In terms of candle structure, this week formed a pin bar with a longer lower shadow (101.49 low), though the close failed to reclaim the intra-week high, suggesting weakening downward momentum on a daily basis. This contrasts with the previous two weeks of continuous decline through early September—this week’s pullback in decline rate may signal a near-term stabilization in the downtrend, though no bottom confirmation yet.
Valuation and Profitability
Current P/E stands at 32.88x and P/B at 3.47x. According to the valuation positioning data, the 5-year percentile is 3.1%, meaning P/E has been cheaper only ~3% of the time in the past five years—an extreme low percentile. This ultra-low valuation itself reflects market anxiety about earnings outlook.
Latest quarterly results (Q2 2026) show EPS of $0.53, down 13.1% sequentially from Q1’s $0.61, and down 47.5% year-over-year. This sharp YoY contraction is the primary driver of valuation suppression. Operating revenue for Q2 was $12.593 billion, up sequentially from Q1’s $11.164 billion and up 13% YoY, yet operating income of $1.852 billion declined sequentially and fell 15.7% YoY. Net profit margin deteriorated from 9.65% in Q1 to 7.37% in Q2.
This reflects a dynamic of revenue growth without profit expansion: top-line is rising but cost pressures or expense increases are eroding margins significantly. The latest consensus forecast (September 9 snapshot) projects full-year EPS of $5.8, with TTM EPS at just $3.1, consistent with the current run rate of $0.5–0.6 per quarter, suggesting lower-half earnings are equally weak. This earnings weakness, not valuation alone, is the key headwind.
Capital Flows
This week reveals a structural divergence: institutional/large-cap buyers posted net inflows of approximately 2,531.75 (relative units) while retail/small-cap investors demonstrated net outflows of approximately 1,996.6. This suggests institutions are accumulating on weakness while retail investors are exiting or cutting losses.
This type of structural divergence appearing amid price decline can signal two scenarios: either large traders are early-positioning for a bottom (resolute accumulation amid weakness), or retail exodus is creating a low-price window for institutional absorption. Looking at the past two months, institutional net flows have persisted for multiple weeks, yet prices continue to break lower, indicating either insufficient institutional buying power to reverse the trend or that the market is repricing earnings expectations downward.
Institutional Views
Current institutional coverage shows 18 analysts with strong buy/buy ratings, 5 with hold, 1 with no opinion, 4 with reduce, and none with sell. Among 28 covering institutions, 78.6% are bullish. The consensus target price is $120.26, implying 18% upside from current levels.
Notably, these ratings were last updated September 11, 2026 (this Friday), so they are not stale. Yet the stark contrast between overwhelmingly bullish ratings and persistent price declines reflects a disconnect: institutional ratings are likely based on medium-term fundamental assumptions, while markets are repricing based on near-term earnings deterioration.
Weekly News Flow
This past week, ABT news centered on several themes:
Product & Regulatory: Abbott received FDA approval for its TactiFlex™ Duo Ablation Catheter for treating cardiac arrhythmias, a significant win for its cardiac rhythm management business. Additionally, it launched the first whole-milk ready-to-feed liquid infant formula in the U.S., expanding its nutrition portfolio.
Institutional Positioning: Multiple institutions adjusted holdings this week, including IFP Advisors increasing exposure, Amundi growing position, and Ally Financial investing $7.35 million. These additions align with bullish institutional ratings but remain routine rebalancing rather than significant accumulation signals.
Stock Performance: Reuters repeatedly noted ABT underperformed peers on Monday, Tuesday, Wednesday, and Friday; weekly recaps highlighted a cumulative -3.68% decline.
Executive Activity: CFO John A. McCoy Jr sold $8,685 in common stock during the month.
News flow lacks major negative catalysts—product approvals are constructive—yet equities continued to decline, signaling market focus has pivoted to earnings deterioration.
Key News Links:
- Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms
- Weekly Recap | Abbott Laboratories -3.68%, most brokers rate it buy
- Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula
- Amundi Grows Position in Abbott Laboratories $ABT
- IFP Advisors Inc Grows Stock Holdings in Abbott Laboratories $ABT
- Ally Financial Inc. Makes New $7.35 Million Investment in Abbott Laboratories $ABT
- Abbott VP, Controller John A. McCoy Jr disposes of common shares worth $8,685.45
- Late-breaking data for Abbott’s TactiFlex™ Duo Ablation Catheter reveal positive outcomes for treating complex AFib cases
- Weekly Recap | Abbott Laboratories -3.58%, dual-sensing device wins FDA nod
- Ieq Capital LLC Invests $17.37 Million in Abbott Laboratories $ABT
Summary
ABT this week faces a core contradiction: extreme valuation compression + institutional consensus bullishness versus deteriorating profitability and lower lows.
Both valuation and institutional ratings point toward oversold territory—P/E at 3rd percentile and 18% upside to target both suggest limited downside risk. Yet sequential earnings deterioration (EPS and net margin both declining) has undermined this case. Institutional inflows failing to arrest the decline indicates either insufficient absorptive capacity or the market awaiting further financial evidence before committing.
Key observations ahead: whether management provides updated guidance or Q3 preannouncements will validate or reverse current negative sentiment. If earnings pressure persists, today’s valuation may not represent a floor; conversely, if the company signals near-term stabilization through cost discipline or product acceleration, institutional backing could spark a rebound. The structural divergence between retail exit and institutional entry suggests institutional conviction remains intact, but proof will come through financial results.